Buscar
Bolt Biotherapeutics Inc
BOLTAñadir a la lista de seguimiento
4.050USD
+0.060+1.50%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
7.78MCap. mercado
PérdidaP/E TTM
Más Datos de Bolt Biotherapeutics Inc Compañía
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Información de Bolt Biotherapeutics Inc
Símbolo de cotizaciónBOLT
Nombre de la empresaBolt Biotherapeutics Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoQuinn (William P)
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección900 Chesapeake Drive
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94063
Teléfono16506659295
Sitio Webhttps://boltbio.com/
Símbolo de cotizaciónBOLT
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoQuinn (William P)
Ejecutivos de Bolt Biotherapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.31K
-1724.25%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.31K
-1724.25%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bolt Biotherapeutics Inc?
Los cinco principales accionistas de Bolt Biotherapeutics Inc son: Mr. William P. (Willie) Quinn
¿Cuántas instituciones poseen acciones de Bolt Biotherapeutics Inc (BOLT)?
A fecha de 2026Q1, 63 instituciones poseen acciones de Bolt Biotherapeutics Inc, con un valor de mercado combinado de aproximadamente 516.47K, lo que representa el 26.88% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -504316.00.